arrow_back Back Filing freshness 10-Q FY 2026 SEC EDGAR

CHAMPIONS ONCOLOGY, INC.

CSBR
$4.82 ▼ -0.08 (-1.63%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
17 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

CHAMPIONS ONCOLOGY, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $66.7M
Dividend Yield —
Revenue Growth 4.4% ↘
Op. Margin -1.9% ↘
ROIC -36.6% ↘
FCF / Share $-0.36 ↘
Trailing P/E —
Price / Book 17.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$59.42M
↑ +4.4% —
Net Income Profit after all expenses
$-1.18M
↓ -125.0% —
Operating Margin Operating profit as % of sales
-1.9%
↓ -124.0% 21th
FCF / Share Free cash flow per share
$-0.36
↓ -171.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
17
Returns
21
Cash Quality ↓
95

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 17 years · 66 quarters